Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study

2018 ◽  
Vol 89 (8) ◽  
pp. 836-843 ◽  
Author(s):  
Marie Abbes ◽  
Eugénie Lhommée ◽  
Stéphane Thobois ◽  
Hélène Klinger ◽  
Emmanuelle Schmitt ◽  
...  

BackgroundReports on behavioural outcomes after subthalamic nucleus deep brain stimulation in Parkinson’s disease are controversial and limited to short-term data. Long-term observation in a large cohort allows a better counselling and management.MethodsTo determine whether a long-term treatment with subthalamic stimulation induces or reduces impulse control behaviours, neuropsychiatric fluctuations and apathy, 69 patients treated with subthalamic stimulation are prospectively and retrospectively assessed using Ardouin Scale of Behavior in Parkinson’s Disease before and after 3–10 years of stimulation.ResultsAt a mean follow-up of 6 years, all impulse control disorders and dopaminergic addiction were significantly decreased, apart from eating behaviour and hypersexuality. Neuropsychiatric fluctuations also significantly improved (ON euphoria: 38% of the patients before surgery and 1% after surgery, P<0.01; OFF dysphoria: 39% of the patients before surgery and 10% after surgery, P<0.01). However, apathy increased (25% of the patients after surgery and 3% before, P<0.01). With the retrospective analysis, several transient episodes of depression, apathy, anxiety and impulse control disorders occurred.ConclusionsBilateral subthalamic nucleus stimulation was overall very effective in improving impulse control disorders and neuropsychiatric fluctuations in parkinsonian patients in the long term despite a counteracting frequent apathy. Transient episodes of impulse control disorders still occurred within the follow-up. These findings recommend a close follow-up in parkinsonian patients presenting with neuropsychiatric symptoms before deep brain stimulation surgery.Clinical trial registrationNCT01705418;Post-results.

2019 ◽  
Vol 10 ◽  
Author(s):  
Robert S. Eisinger ◽  
Adolfo Ramirez-Zamora ◽  
Samuel Carbunaru ◽  
Brandon Ptak ◽  
Zhongxing Peng-Chen ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Polyvios Demetriades ◽  
Hugh Rickards ◽  
Andrea Eugenio Cavanna

Parkinson's disease (PD) has been associated with the development of impulse control disorders (ICDs), possibly due to overstimulation of the mesolimbic system by dopaminergic medication. Preliminary reports have suggested that deep brain stimulation (DBS), a neurosurgical procedure offered to patients with treatment-resistant PD, affects ICD in a twofold way. Firstly, DBS allows a decrease in dopaminergic medication and hence causes an improvement in ICDs. Secondly, some studies have proposed that specific ICDs may develop after DBS. This paper addresses the effects of DBS on ICDs in patients with PD. A literature search identified four original studies examining a total of 182 patients for ICDs and nine case reports of 39 patients that underwent DBS and developed ICDs at some point. Data analysis from the original studies did not identify a significant difference in ICDs between patients receiving dopaminergic medication and patients on DBS, whilst the case reports showed that 56% of patients undergoing DBS had poor outcome with regards to ICDs. We discuss these ambivalent findings in the light of proposed pathogenetic mechanisms. Longitudinal, prospective studies with larger number of patients are required in order to fully understand the role of DBS on ICDs in patients with PD.


2002 ◽  
Vol 23 (0) ◽  
pp. s111-s112 ◽  
Author(s):  
A. Tavella ◽  
B. Bergamasco ◽  
E. Bosticco ◽  
M. Lanotte ◽  
P. Perozzo ◽  
...  

2010 ◽  
Vol 16 (5) ◽  
pp. 334-337 ◽  
Author(s):  
Melis Sohtaoğlu ◽  
Derya Yavuz Demiray ◽  
Gülay Kenangil ◽  
Sibel Özekmekçi ◽  
Ethem Erginöz

2016 ◽  
Vol 28 (10) ◽  
pp. 1597-1614 ◽  
Author(s):  
Susan Zhang ◽  
Nadeeka N. Dissanayaka ◽  
Andrew Dawson ◽  
John D. O'Sullivan ◽  
Philip Mosley ◽  
...  

ABSTRACTBackground:Impulse control disorders (ICDs) have become a widely recognized non-motor complication of Parkinson's disease (PD) in patients taking dopamine replacement therapy (DRT). There are no current evidence-based recommendations for their treatment, other than reducing their dopaminergic medication.Methods:This study reviews the current literature of the treatment of ICDs including pharmacological treatments, deep brain stimulation, and psychotherapeutic interventions.Results:Dopamine agonist withdrawal is the most common and effective treatment, but may lead to an aversive withdrawal syndrome or motor symptom degeneration in some individuals. There is insufficient evidence for all other pharmacological treatments in treating ICDs in PD, including amantadine, serotonin selective reuptake inhibitors, antipsychotics, anticonvulsants, and opioid antagonists (e.g. naltrexone). Large randomized control trials need to be performed before these drugs can be routinely used for the treatment of ICDs in PD. Deep brain stimulation remains equivocal because ICD symptoms resolve in some patients after surgery but may appearde novoin others. Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed.Conclusions:Further research will allow for the development of evidence-based guidelines for the management of ICDs in PD.


Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P02.238-P02.238
Author(s):  
F. Durif ◽  
D. Morand ◽  
B. Pereira ◽  
J.-J. Lemaire ◽  
P. Derost ◽  
...  

2015 ◽  
Vol 30 (5) ◽  
pp. 696-704 ◽  
Author(s):  
Chiara Siri ◽  
Roberto Cilia ◽  
Elisa Reali ◽  
Beatrice Pozzi ◽  
Emanuele Cereda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document